

흰쥐의 갑상인두근과 운상인두근에서 Myosin Heavy Chain mRNA 아형의 정량적 분석

박영실¹ · 정학현² · 남순열¹

Quantitative Analysis of Myosin Heavy Chain (MHC) mRNA Expression in Thyropharyngeus Muscle and Cricopharyngeus Muscle in Rats

Young Sil Park, MD¹, Hak Hyun Jung, MD² and Soon Yhul Nam, MD¹

*1*Department of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine, Seoul,

*2*Department of Otolaryngology-Head and Neck Surgery, Korea University College of Medicine, Seoul, Korea

ABSTRACT

Background and Objectives : The inferior pharyngeal constrictor muscle (IPC), which consists of the thyropharyngeus (TP) and cricopharyngeus (CP) muscles, plays an important role during deglutition, but their function is different when analysed by radiographic, manometric and electromyographic studies. **Materials :** The purpose of this study is to quantify the expression levels of MHC mRNA isoforms (2B, 2X, 2A, 2L, b-cardiac, neonatal and embryonic) in thyropharyngeus and cricopharyngeus muscles of rats using the competitive PCR. **Results :** The thyropharyngeus muscle was mainly consisted of three fast-twitching MHC isoforms, mostly 2X isoform (85.2%). On the other hand, the cricopharyngeus muscle contained two-third of fast-twitching isoforms (65.1%) and one-third of neonatal MHC (34.9%). **Conclusions :** The thyropharyngeus muscle could be characterized as a fast-twitching muscle and the cricopharyngeus muscle is probably considered as a sarcomeric regenerating muscle that is caused by frequent mechanical damage during deglutition. (**Korean J Otolaryngol 2000;43:300-5**)

KEY WORDS : Competitive PCR · Gene expression · Thyropharyngeus muscle · Cricopharyngeus muscle · Rat.

neonatal MHC, embryonic MHC³⁻⁹⁾
 2A MHC, 2B MHC, 2X MHC
 , 2B
 (myosin) (skeletal muscle) 가 MHC 가 ,
 2A MHC 2B MHC
 (myosin heavy chain, MHC) , 2X MHC 2B MHC 2A MHC
 (myosin light chain, MLC)⁴⁾ (intrinsic laryn-
 , MHC , geal muscle) (extraocular muscles)
 MLC MHC 가¹⁾²⁾ 2L MHC가 ,
 MHC RNA(messenger RNA, mRNA) 가
 8가 , , 2A MHC, 2B MHC,
 2X MHC, 2L MHC, - cardiac MHC, - cardiac MHC,
 : 1999 9 22 / : 1999 12 30
 : , 138 - 736 388 - 1
 : 02) 2224 - 3966 · : 02) 489 - 2773
 E - mail : synam@www.amc.seoul.kr

1)8) Neonatal MHC embryonic MHC

11)12)
(inferior pharyngeal constrictor)
(thyropharyngeus mu -
(cricopharyngeus muscle)

200 300 g Sprague - Dawley
(50 mg/kg) Ketamine hydrochloride

가 1 3 - 70
isopentane
- 70

type , ATPase type PCR
PCR (primer) MHC 3'
620 660
가 (sense primer)
MHC 가
(degenerated oligonucleotide)
(antisense primer)
MHC mRNA 가
3' 가
(Table 1).⁹⁾¹⁰⁾

actin (Table 1).
, 2L MHC, neonatal MHC, embryonic MHC
mRNA MHC mRNA
, MHC mRNA
(homology)
(Northern blotting), (in situ hy -
bridization), RNase (RNase protection
assay)
MHC mRNA
polymerase chain reaction,
mol) , MHC mRNA
, attomol(10^{-18})
- PCR
MHC mRNA
MHC mRNA

PCR (PCR competitor)
MHC mRNA (competitor) 1
7 (2A MHC, 2B MHC,
2X MHC, 2L MHC, - cardiac MHC, - cardiac MHC,
neonatal MHC, embryonic MHC) 40 80 bp
, PCR 2A MHC(Genebank
accession No. L13606) 400 bp DNA
⁹⁾¹⁰⁾
AGAAGGCCAAGAAAGCCAT 가
- actin 178 bp
DNA - actin
¹⁰⁾ pGEM - T
vecor(Promega, Madison, WI, USA) ABI
373 A automated DNA sequencing system(ABI)
PCR
MHC mRNA PCR (613
683 bp) 119 168 bp (Table 1).

Myosin Heavy Chain mRNA

Table 1. Oligonucleotide sequences and the expected length of PCR products of MHC transcripts and competitor

Primers	Oligonucleotide sequences	Expected length of PCR products	
		MHC transcripts (competitor)	
Sense primers	5AGAAGGCCAARAARGCCAT3		
consensus	5GAGAAGAGCTATGAGCTGCC3		
-actin			
Antisense primers			
-actin	5CCAATCCACACAGAGTACTTG3	295 bp	(219 bp)
2A	5TTACAATAGGATTAAATAGAA3	644 bp	(519 bp)
2B	5TTGATATACAGGACAGTGACA3	624 bp	(458 bp)
2X	5TTTTTATCTCCCAAAGTCG3	645 bp	(478 bp)
2L	5CCCAGTCTCCCTCTGCTCT3	605 bp	(437 bp)
neonatal	5AGTCAGCAGTGGGAGAAAAG3	658 bp	(539 bp)
embryonic	5ATGTGGAAAGGGGTACGT3	683 bp	(558 bp)
-cardiac	5TTTCTGCCTGAAGGTGCTGT3	613 bp	(498 bp)

PCR (Life Technologies, Gaithersburg, MD, USA) RNA(total RNA) , RNA 0.5 μg Superscript Preamplication System(Life Technologies, Gaithersburg, MD, USA) cDNA 4 80 μl cDNA MHC mRNA 1 μl , 7 PCR 2% 가 PCR (Ethidium bromide) 2% 가 (300 dots/in) HP deskscan (Hewlett - Packard, Palo Alto, CA) Na - tional Institute of Health Image software(version 1.60) PCR (Optical density) (linear regression analysis) MHC PCR pGEM - T vector(Promega, Madison, WI, USA) ABI 373A automated DNA sequencing system(ABI) . cDNA MHC mRNA 가 cDNA 1 μl 3 1 μl MHC mRNA PCR 1 fmol(10⁻¹⁵ mol), 0.333 fmol, 0.111 fmol, 0.037 fmol, 0.0123 fmol, 0.00412 fmol, 0.00137 fmol, 0.000457 fmol, 0.000152 fmol, 0.000051 fmol(0.051 amol) . RT - PCR 2A MHC, 2B MHC, 2X MHC, neonatal MHC , - cardiac MHC , em - bryonic MHC 2L MHC (Fig. 1). PCR MHC mRNA 2X MHC, 2B MHC, 2A MHC 18.9 ± 1.9 amoles, 1.7 ± 0.2 amoles, 1.6 ± 0.3 amoles , neonatal MHC 0.01 amoles




Fig. 1. MHC mRNA isoforms and β -actin on a 2% agarose gel by competitive PCR of cDNA from the thyropharyngeus muscle and cricopharyngeus muscle. L is 100 bp ladder with the bright bands (arrowheads) representing 600 bp. Symbol (+) means a RT-PCR band of MHC mRNA transcripts without competitor. For competitive PCR, the initial concentration of the competitor was 1 fmol (lane 1) and 3-fold serial dilutions, such as 333 amoles (2), 111 amoles (3), 37 amoles (4), 12.3 amoles (5), 4.12 amoles (6), 1.37 amoles (7), 0.46 amoles (8), 0.15 amoles (9), and 0.05 amoles (10) were used. Upper bands of the PCR products are targets and lower bands are competitors. Arrows point to approximate concentration at which target and competitor are at the same concentration. The thyropharyngeus muscle expressed predominant 2X MHC with lesser percentage of 2A MHC and 2B MHC. The cricopharyngeus muscle expressed predominant neonatal MHC. Approximately equal percentage of 2X MHC, 2A MHC, and 2B MHC were expressed. Neo; neonatal MHC, Emb; embryonic MHC, β -car; β -cardiac MHC.

Table 2. Myosin heavy chain (MHC) mRNA composition of Thyropharyngeus and Cricopharyngeus muscle in rats

MHC isoforms	Composition, %	
	Thyropharyngeus muscle	Cricopharyngeus muscle
2A	7.0 \pm 1.5% (1.6 \pm 0.3)	27.9 \pm 6.8% (2.4 \pm 0.6)
2B	7.5 \pm 0.9% (1.7 \pm 0.2)	19.8 \pm 1.4% (1.7 \pm 0.1)
2X	85.1 \pm 8.6% (18.9 \pm 1.9)	17.4 \pm 2.5% (1.5 \pm 0.2)
2L	ND	ND
Neonatal	<0.1% (<0.01)	34.9 \pm 4.2% (3.0 \pm 0.4)
Embryonic	ND	ND
β -cardiac	ND	<0.1% (<0.01)
β -actin	(5.4 \pm 0.6)	(3.1 \pm 0.5)

Values are mean \pm SE. Three competitive PCRs were performed on cDNA of each muscle and gels were scanned once and the peaks were selected 3 times. Abbreviations: ND, not detected

2X MHC가 85.1% \pm 8.6 가
 , 2B MHC 7.6% \pm 0.9, 2A MHC 7.2% \pm 1.5
 neonatal MHC 0.1% . 2L MHC,
 β -cardiac MHC, embryonic MHC
 neonatal MHC, 2A MHC, 2B MHC,
 2X MHC , 3.0 \pm 0.1 amo -
 les, 2.4 \pm 0.6 amoles, 1.7 \pm 0.2 amoles, 1.5 \pm 0.1 amoles

, β -cardiac MHC 0.01 amoles .
 neonatal MHC가 34.9% \pm 4.2 가
 , 2A MHC, 2B MHC, 2X MHC 27.9% \pm 6.8,
 19.8% \pm 1.4, 17.4% \pm 2.5 , β -cardiac MHC 0.1%
 2L MHC
 embryonic MHC (Table 2, Fig. 1).
 β -actin
 3.1 \pm 0.1 amol, 5.4 \pm 0.3 amol

PCR MHC
 mRNA
 (RNase protection assay)
 RNase
 0.01 amol 가
 cDNA
 mRNA (1994)²⁰⁾ Ferr
 molecules), RNase (RNase protection assay)
 5 \times 10⁵ 10⁶ (target molecules)
 PCR 10 100 가

Myosin Heavy Chain mRNA

2A, 2B, 2X 100% ,
 65.1% .
 ATPase 2 가 가 ,²²⁾ 가
 1 가 , neonatal MHC
 가
¹⁶⁾ ,
 2 2X MHC
 가 85.1%
 2X MHC (vocalis mu -
 scles), (diaphragmatic muscles), (masseter
 muscles) , MHC
 2X MHC가 80.6%, 63.9%, 43.5%
⁹⁾¹⁰⁾ ,
 1 - cardiac MHC
 0.1 %
 가
 (upper esophageal sphincter)
 Brooke Kaiser²¹⁾ 2C
 가 ,
 2C 1.3%,
 3.6% ¹⁶⁾
 neonatal MHC 34.9%
 MHC neonatal MHC
 가
 , 1%
⁹⁾¹⁰⁾ .
 neonatal MHC가
 (branchial cleft)
 , neonatal MHC
 (isotyping swit -
 ching)
 (in vitro)

(endomysial connective tissue)
 가
 ,
 PCR
 MHC mRNA ,
 2X MHC가 가
 MHC
 ,
 65%
 , neonatal MHC가
 : PCR .

REFERENCES

- 1) Emerson CP. *Molecular genetics of myosin. Am Rev Biochem* 1987; 56:695-726.
- 2) Bottinelli R, Schiaffino S, Reggiani C. *Force-velocity relations and myosin heavy chain isoform compositions of skinned fibers from rat skeletal muscle. J Physiol* 1991;437:655-72.
- 3) Lieber RL, Bodine SC, Burkholder TJ, Pierotti DJ, Ryan AF. *Cloning and in situ hybridization of type 2A and 2B rat skeletal muscle myosin tail region implications for filament assembly. Biochem Biophys Res Comm* 1993;197:1312-8.
- 4) DeNardi C, Ausoni S, Moretti P, et al. *Type 2X-myosin heavy chain is coded by a muscle fiber type-specific and developmentally regulated gene. J Cell Biol* 1993;123:823-35.
- 5) Merati AL, Bodine SC, Bennett T, Jung HH, Furata H, Ryan AF. *Identification of a novel myosin heavy chain gene expressed in the rat larynx. Biochim Biophys Acta* 1996;1306:153-9.
- 6) Periasamy M, Wydro RM, Strehler-Page MA, Strehler EE, Nada-Ginard B. *Characterization of cDNA and genomic sequences corresponding to an embryonic myosin heavy chain. J Biol Chem* 1985;260:15856-62.
- 7) Periasamy M, Wieczorek DF, Nadal-Ginard B. *Characterization of a developmentally regulated perinatal myosin heavy-chain gene expressed in skeletal muscle. J Biol Chem* 1984;259:13573-8.
- 8) McNally EM, Kraft R, Bravo-Sehnder M, Taylor DA, Leinwand LA. *Fulllength rat alpha and beta cardiac myosin heavy chain sequences: Comparisons suggest a molecular basis for functional differences. J Mol Biol* 1989;210:665-71.
- 9) Jung HH, Han SH, Choi JO. *Expression Levels of Myosin Heavy Chain mRNA in Rat Laryngeal Muscles. Acta Otolaryngol (Stockh)* 1999;119:396-402.
- 10) Jung HH, Lieber RL, Ryan AF. *Quantification of myosin heavy chain mRNA levels in somatic and branchial arch skeletal muscles using competitive PCR. Am J Physiol* 1998;275:C68-74.
- 11) Gorza L, Sartore S, Triban C, Schiaffino S. *Embryonic-like-myosin heavy chains in regenerating chick muscle. Exp Cell Res* 1983;

- 143:395-403.
- 12) Schiaffino S, Gorza L, Pitton G, Saggin L, Ausoni S, Sartore S, et al. Embryonic and neonatal myosin heavy chain in denervated and paralyzed rat skeletal muscle. *Dev Biol* 1988;127:1-11.
 - 13) Mendelsohn MS, McConnel FM. Function in the pharyngoesophageal segment. *Laryngoscope* 1987;97:483-9.
 - 14) Kelly JH, Kuncel RW. Myology of the pharyngoesophageal segment: Gross anatomic and histologic characteristics. *Laryngoscope* 1996;106:713-20.
 - 15) Medda BK, Lang IM, Dodds WJ, Christl M, Kern M, Hogan WJ, et al. Correlation of electrical and contractile activities of the cricopharyngeus muscle in the cat. *Am J Physiol* 1997;273:G470-9.
 - 16) Hyodo M, Aibara R, Kawakita S, Yumoto E. Histopathological study of the canine inferior pharyngeal constrictor muscle: Implications for its function. *Acta Otolaryngol (Stich)* 1998;118: 272-9.
 - 17) Shindo ML, Herzon GD, Hanson DG, Cain DJ, Sahgal CV. Effects of denervation of laryngeal muscles; A canine model. *Laryngoscope* 1992;102:663-9.
 - 18) Classen H, Werner JA. Fiber differentiation of the human laryngeal muscles using the inhibition reactivation myofibrillar ATPase technique. *Anat Embryol* 1992;186:341-6.
 - 19) DelGaudio JM, Sciote JJ, Carroll WR, Esclamado RM. Atypical myosin heavy chain in rat laryngeal muscle. *Ann Otol Rhinol Laryngol* 1995;104:237-45.
 - 20) Ferre F, Marchese A, Pezzoli P, Griffin S, Buxton E, Boyer V. Quantative PCR. In: Mullis KB, Ferre F, Gibbs RA editors the Polymerase chain reaction. Boston: Birkhauser;1994. p.67-88.
 - 21) Brooke MH, Kaiser KK. Muscle fibre types: How many and what kind? *Archives of Neurology* 1970;23:369-79.
 - 22) Bonington A, Mahon M, Whitmore I. A histological and histochemical study of the cricopharyngeus muscle in man. *J Anat* 1988; 156:27-37.